Guselkumab for the treatment of psoriasis: a 60-week real-life multicenter retrospective experience.

Background: Real-world data for guselkumab, the first interleukin-23 inhibitor approved to treat moderate-to-severe psoriasis, are scarce. This study represents the first 60-week, real-life, multicenter, retrospective experience to investigate the effectiveness, safety, tolerability, and drug retention of guselkumab in psoriatic patients.

Research Design And Methods: Clinical information was collected at baseline and at weeks 12, 24, 36, 48, and 60.

Femoral neck fracture: the reliability of radiologic classifications.

Background: Femoral neck fractures (FNF) are one of the most common injury in the elderly. A valid radiographic classification system is mandatory to perform the correct treatment and to allow surgeons to facilitate communication. This study aims to evaluate reliability of 2018 AO/OTA Classification, AO/OTA simplified and Garden classification.

Use of Apremilast® in the psoriasis treatment: a real-life multicenter Italian experience.

Background: Apremilast (Amgen, Thousand Oaks, CA, USA) is the first small molecule approved for the treatment of moderate-to-severe psoriasis in adult patients; however, real-life data are still limited. We investigated the effectiveness and safety of this drug in a multicenter real-world setting.

Methods: We retrospectively reviewed data from all psoriatic patients who received at least one dose of Apremilast (Amgen) and collected demographic data and medical history at baseline and periodically for 36 months.